| Year |
Citation |
Score |
| 2020 |
Marquis-Gravel G, Dalgaard F, Jones AD, Lokhnygina Y, James SK, Harrington RA, Wallentin L, Steg PG, Lopes RD, Storey RF, Goodman SG, Mahaffey KW, Tricoci P, White HD, Armstrong PW, et al. Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCI. Journal of the American College of Cardiology. 76: 162-171. PMID 32646565 DOI: 10.1016/J.Jacc.2020.05.031 |
0.354 |
|
| 2020 |
Bethel MA, Stevens SR, Buse JB, Choi J, Gustavson SM, Iqbal N, Lokhnygina Y, Mentz RJ, Patel RA, Öhman P, Schernthaner G, Lecube A, Hernandez AF, Holman RR. Exploring the Possible Impact of Unbalanced Open-Label Drop-In of Glucose-Lowering Medications on EXSCEL Outcomes. Circulation. PMID 32098501 DOI: 10.1161/Circulationaha.119.043353 |
0.348 |
|
| 2020 |
Black-Maier E, Steinberg BA, Trulock KM, Wang F, Lokhnygina Y, O'Neal W, Al-Khatib S, Atwater BD, Daubert JP, Frazier-Mills C, Hegland DD, Jackson KP, Jackson LR, Koontz JI, Lewis RK, et al. Effectiveness of catheter ablation of atrial fibrillation according to heart failure etiology. Journal of Arrhythmia. 36: 84-92. PMID 32071625 DOI: 10.1002/Joa3.12291 |
0.311 |
|
| 2019 |
Bethel MA, Mentz RJ, Merrill P, Buse JB, Chan JC, Goodman SG, Iqbal N, Jakuboniene N, Katona B, Lokhnygina Y, Lopes RD, Maggioni AP, Ohman P, Tankova T, Bakris GL, et al. Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial. Diabetes Care. PMID 31757838 DOI: 10.2337/Dc19-1065 |
0.322 |
|
| 2019 |
Fudim M, White J, Pagidipati NJ, Lokhnygina Y, Wainstein J, Murin J, Iqbal N, Öhman P, Lopes RD, Reicher B, Holman RR, Hernandez AF, Mentz RJ. Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes With and Without Heart Failure and Heart Failure-Related Outcomes: Insights From the EXSCEL Trial. Circulation. PMID 31542942 DOI: 10.1161/Circulationaha.119.041659 |
0.35 |
|
| 2019 |
Nauck MA, McGuire DK, Pieper KS, Lokhnygina Y, Strandberg TE, Riefflin A, Delibasi T, Peterson ED, White HD, Scott R, Holman RR. Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS. Cardiovascular Diabetology. 18: 116. PMID 31481069 DOI: 10.1186/S12933-019-0921-2 |
0.383 |
|
| 2019 |
Bach RG, Cannon CP, Giugliano RP, White JA, Lokhnygina Y, Bohula EA, Califf RM, Braunwald E, Blazing MA. Effect of Simvastatin-Ezetimibe Compared With Simvastatin Monotherapy After Acute Coronary Syndrome Among Patients 75 Years or Older: A Secondary Analysis of a Randomized Clinical Trial. Jama Cardiology. PMID 31314050 DOI: 10.1001/Jamacardio.2019.2306 |
0.386 |
|
| 2019 |
Guimarães PO, Peterson ED, Stevens SR, Lokhnygina Y, Green JB, McGuire DK, Holman RR, Lopes RD. Antithrombotic treatment gap among patients with atrial fibrillation and type 2 diabetes. International Journal of Cardiology. PMID 31079973 DOI: 10.1016/J.Ijcard.2019.04.085 |
0.368 |
|
| 2019 |
Doll JA, Jones WS, Lokhnygina Y, Culpepper S, Parks RL, Calhoun C, Au DH, Patel MR. PREPARED Study: A Study of Shared Decision-Making for Coronary Artery Disease. Circulation. Cardiovascular Quality and Outcomes. 12: e005244. PMID 30764651 DOI: 10.1161/Circoutcomes.118.005244 |
0.361 |
|
| 2019 |
Sharma A, Sun JL, Lokhnygina Y, Roe MT, Ahmad T, Desai NR, Blazing MA. Patient Phenotypes, Cardiovascular Risk, and Ezetimibe Treatment in Patients After Acute Coronary Syndromes (from IMPROVE-IT). The American Journal of Cardiology. PMID 30739657 DOI: 10.1016/J.Amjcard.2019.01.034 |
0.354 |
|
| 2019 |
Navar AM, Roe MT, White JA, Cannon CP, Lokhnygina Y, Newby LK, Giugliano RP, Tershakovec AM, Braunwald E, Califf RM, Blazing MA. Medication Discontinuation in the IMPROVE-IT Trial. Circulation. Cardiovascular Quality and Outcomes. 12: e005041. PMID 30630361 DOI: 10.1161/Circoutcomes.118.005041 |
0.309 |
|
| 2018 |
Mentz RJ, Bethel MA, Merrill P, Lokhnygina Y, Buse JB, Chan JC, Felício JS, Goodman SG, Choi J, Gustavson SM, Iqbal N, Lopes RD, Maggioni AP, Öhman P, Pagidipati NJ, et al. Effect of Once-Weekly Exenatide on Clinical Outcomes According to Baseline Risk in Patients With Type 2 Diabetes Mellitus: Insights From the EXSCEL Trial. Journal of the American Heart Association. 7: e009304. PMID 30371301 DOI: 10.1161/Jaha.118.009304 |
0.368 |
|
| 2018 |
Ambrosy AP, Cerbin LP, Fudim M, Clare RM, Lokhnygina Y, Braunwald E, Califf RM, Cannon CP, Tershakovec AM, Roe MT, Blazing MA. Natural History of Patients Postacute Coronary Syndrome Based on Heart Failure Status. The American Journal of Cardiology. PMID 30180960 DOI: 10.1016/J.Amjcard.2018.07.034 |
0.366 |
|
| 2018 |
Davis TME, Mulder H, Lokhnygina Y, Aschner P, Chuang LM, Raffo Grado CA, Standl E, Peterson ED, Holman RR. Effect of race on the glycaemic response to sitagliptin: Insights from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). Diabetes, Obesity & Metabolism. PMID 29405540 DOI: 10.1111/Dom.13242 |
0.329 |
|
| 2018 |
Kochar A, Hellkamp AS, Lokhnygina Y, Jones WS, Becker RC, Berkowitz SD, Breithardt G, Fox KAA, Halperin JL, Hankey GJ, Mahaffey KW, Nessel CC, Singer DE, Piccini JP, Patel MR. Efficacy and safety of rivaroxaban compared with warfarin in patients with carotid artery disease and nonvalvular atrial fibrillation: Insights from the ROCKET AF trial. Clinical Cardiology. PMID 29389037 DOI: 10.1002/Clc.22846 |
0.352 |
|
| 2018 |
Fordyce C, Roe M, Sharma A, Page C, White J, Lokhnygina Y, Blazing M. Sentinel Events Prior To Sudden Cardiac Death Among Clinically Stable Acute Coronary Syndrome Patients: Insights From The Improve-It Trial Journal of the American College of Cardiology. 71. DOI: 10.1016/S0735-1097(18)30634-X |
0.405 |
|
| 2017 |
Bethel MA, Patel RA, Merrill P, Lokhnygina Y, Buse JB, Mentz RJ, Pagidipati NJ, Chan JC, Gustavson SM, Iqbal N, Maggioni AP, Öhman P, Poulter NR, Ramachandran A, Zinman B, et al. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. The Lancet. Diabetes & Endocrinology. PMID 29221659 DOI: 10.1016/S2213-8587(17)30412-6 |
0.307 |
|
| 2017 |
Sharma A, Green JB, Dunning A, Lokhnygina Y, Al-Khatib SM, Lopes RD, Buse JB, Lachin JM, Van de Werf F, Armstrong PW, Kaufman KD, Standl E, Chan JCN, Distiller LA, Scott R, et al. Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial. Diabetes Care. PMID 28986504 DOI: 10.2337/Dc17-1091 |
0.319 |
|
| 2017 |
Fanaroff AC, Roe MT, Clare RM, Lokhnygina Y, Navar AM, Giugliano RP, Wiviott SD, Tershakovec AM, Braunwald E, Blazing MA. Competing Risks of Cardiovascular Versus Noncardiovascular Death During Long-Term Follow-Up After Acute Coronary Syndromes. Journal of the American Heart Association. 6. PMID 28923989 DOI: 10.1161/Jaha.117.005840 |
0.384 |
|
| 2017 |
Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, Maggioni AP, Marso SP, Öhman P, Pagidipati NJ, Poulter N, et al. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. The New England Journal of Medicine. PMID 28910237 DOI: 10.1056/Nejmoa1612917 |
0.412 |
|
| 2017 |
Navar AM, Gallup DS, Lokhnygina Y, Green JB, McGuire DK, Armstrong PW, Buse JB, Engel SS, Lachin JM, Standl E, Van de Werf F, Holman RR, Peterson ED. Hypertension Control in Adults With Diabetes Mellitus and Recurrent Cardiovascular Events: Global Results From the Trial Evaluating Cardiovascular Outcomes With Sitagliptin. Hypertension (Dallas, Tex. : 1979). PMID 28847886 DOI: 10.1161/Hypertensionaha.117.09482 |
0.31 |
|
| 2017 |
Washam JB, Hellkamp AS, Lokhnygina Y, Piccini JP, Berkowitz SD, Nessel CC, Becker RC, Breithardt G, Fox KAA, Halperin JL, Hankey GJ, Mahaffey KW, Singer DE, Patel MR. Efficacy and Safety of Rivaroxaban Versus Warfarin in Patients Taking Nondihydropyridine Calcium Channel Blockers for Atrial Fibrillation (from the ROCKET AF Trial). The American Journal of Cardiology. PMID 28645473 DOI: 10.1016/J.Amjcard.2017.05.026 |
0.391 |
|
| 2017 |
Pagidipati NJ, Navar AM, Pieper KS, Green JB, Bethel MA, Armstrong PW, Josse RG, McGuire DK, Lokhnygina Y, Cornel JH, Halvorsen S, Strandberg TE, Delibasi T, Holman RR, Peterson ED, et al. Secondary Prevention of Cardiovascular Disease in Patients with Type 2 Diabetes: International Insights from the TECOS Trial. Circulation. PMID 28626088 DOI: 10.1161/Circulationaha.117.027252 |
0.377 |
|
| 2017 |
Stanifer JW, Charytan DM, White J, Lokhnygina Y, Cannon CP, Roe MT, Blazing MA. Benefit of Ezetimibe Added to Simvastatin in Reduced Kidney Function. Journal of the American Society of Nephrology : Jasn. PMID 28507057 DOI: 10.1681/Asn.2016090957 |
0.327 |
|
| 2017 |
Balla SR, Cyr DD, Lokhnygina Y, Becker RC, Berkowitz SD, Breithardt G, Fox KAA, Hacke W, Halperin JL, Hankey GJ, Mahaffey KW, Nessel CC, Piccini JP, Singer DE, Patel MR. Relation of Risk of Stroke in Patients With Atrial Fibrillation to Body Mass Index (from Patients Treated With Rivaroxaban and Warfarin in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation Trial). The American Journal of Cardiology. PMID 28477860 DOI: 10.1016/J.Amjcard.2017.03.028 |
0.341 |
|
| 2017 |
Sun Y, Hu D, Stevens S, Lokhnygina Y, Becker RC, Berkowitz SD, Breithardt G, Hacke W, Halperin JL, Hankey GJ, Mahaffey KW, Nessel CC, Piccini JP, Singer DE, Fox KAA, et al. Efficacy and safety of rivaroxaban versus warfarin in patients from mainland China with nonvalvular atrial fibrillation: A subgroup analysis from the ROCKET AF trial. Thrombosis Research. PMID 28433206 DOI: 10.1016/J.Thromres.2017.04.010 |
0.354 |
|
| 2017 |
Valgimigli M, Costa F, Lokhnygina Y, Clare RM, Wallentin L, Moliterno DJ, Armstrong PW, White HD, Held C, Aylward PE, Van de Werf F, Harrington RA, Mahaffey KW, Tricoci P. Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial. European Heart Journal. 38: 804-810. PMID 28363222 DOI: 10.1093/Eurheartj/Ehw525 |
0.405 |
|
| 2017 |
Lindner SM, Fordyce CB, Hellkamp AS, Lokhnygina Y, Piccini JP, Breithardt G, Mahaffey KW, Singer DE, Hacke W, Halperin JL, Hankey GJ, Berkowitz SD, Nessel CC, Becker RC, Fox KA, et al. Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin: A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis. Circulation. 135: 1001-1003. PMID 28264892 DOI: 10.1161/Circulationaha.116.024666 |
0.389 |
|
| 2017 |
Farhan S, Clare RM, Jarai R, Giugliano RP, Lokhnygina Y, Harrington RA, Kristin Newby L, Huber K. Fasting glucose, NT-proBNP, treatment with eptifibatide, and outcomes in non-ST-segment elevation acute coronary syndromes: An analysis from EARLY ACS. International Journal of Cardiology. PMID 28089149 DOI: 10.1016/J.Ijcard.2017.01.007 |
0.322 |
|
| 2016 |
Blazing MA, Giugliano RP, de Lemos JA, Cannon CP, Tonkin A, Ballantyne CM, Lewis BS, Musliner TA, Tershakovec AM, Lokhnygina Y, White JA, Reist C, McCagg A, Braunwald E. On-treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT). American Heart Journal. 182: 89-96. PMID 27914504 DOI: 10.1016/J.Ahj.2016.09.004 |
0.354 |
|
| 2016 |
Shah R, Hellkamp A, Lokhnygina Y, Becker RC, Berkowitz SD, Breithardt G, Hacke W, Halperin JL, Hankey GJ, Fox KA, Nessel CC, Mahaffey KW, Piccini JP, Singer DE, Patel MR, et al. Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial. American Heart Journal. 179: 77-86. PMID 27595682 DOI: 10.1016/J.Ahj.2016.05.019 |
0.406 |
|
| 2016 |
Åkerblom A, Clare RM, Lokhnygina Y, Wallentin L, Held C, Van de Werf F, Moliterno DJ, Patel UD, Leonardi S, Armstrong PW, Harrington RA, White HD, Aylward PE, Mahaffey KW, Tricoci P. Albuminuria and cardiovascular events in patients with acute coronary syndromes: Results from the TRACER trial. American Heart Journal. 178: 1-8. PMID 27502846 DOI: 10.1016/J.Ahj.2016.04.013 |
0.407 |
|
| 2016 |
McGuire DK, Van de Werf F, Armstrong PW, Standl E, Koglin J, Green JB, Bethel MA, Cornel JH, Lopes RD, Halvorsen S, Ambrosio G, Buse JB, Josse RG, Lachin JM, Pencina MJ, ... ... Lokhnygina Y, et al. Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial. Jama Cardiology. 1: 126-35. PMID 27437883 DOI: 10.1001/Jamacardio.2016.0103 |
0.345 |
|
| 2016 |
Hess PL, Wojdyla DM, Al-Khatib SM, Lokhnygina Y, Wallentin L, Armstrong PW, Roe MT, Ohman EM, Harrington RA, Alexander JH, White HD, Van de Werf F, Piccini JP, Held C, Aylward PE, et al. Sudden Cardiac Death After Non-ST-Segment Elevation Acute Coronary Syndrome. Jama Cardiology. 1: 73-9. PMID 27437658 DOI: 10.1001/Jamacardio.2015.0359 |
0.343 |
|
| 2016 |
Fordyce CB, Hellkamp AS, Lokhnygina Y, Lindner SM, Piccini JP, Becker RC, Berkowitz SD, Breithardt G, Fox KA, Mahaffey KW, Nessel CC, Singer DE, Patel MR. On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF. Circulation. 134: 37-47. PMID 27358435 DOI: 10.1161/Circulationaha.116.021890 |
0.386 |
|
| 2016 |
Harskamp RE, Clare RM, Ambrosio G, Held C, Lokhnygina Y, Moliterno DJ, White HD, Aylward PE, Armstrong PW, Mahaffey KW, Harrington RA, Van de Werf F, Wallentin L, Strony J, Tricoci P. Use of thienopyridine prior to presentation with non-ST-segment elevation acute coronary syndrome and association with safety and efficacy of vorapaxar: insights from the TRACER trial. European Heart Journal. Acute Cardiovascular Care. PMID 26895973 DOI: 10.1177/2048872616633880 |
0.386 |
|
| 2016 |
Murphy SA, Cannon CP, Blazing MA, Giugliano RP, White JA, Lokhnygina Y, Reist C, Im K, Bohula EA, Isaza D, Lopez-Sendon J, Dellborg M, Kher U, Tershakovec AM, Braunwald E. Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT Trial. Journal of the American College of Cardiology. 67: 353-61. PMID 26821621 DOI: 10.1016/J.Jacc.2015.10.077 |
0.4 |
|
| 2016 |
Boggan AMN, White J, Lokhnygina Y, Newby LK, Blazing M. Evaluation Of Medication Persistence In The Improve-It Trial Journal of the American College of Cardiology. 67: 620. DOI: 10.1016/S0735-1097(16)30621-0 |
0.304 |
|
| 2016 |
Costa F, Valgimigli M, Lokhnygina Y, Clare R, Wallentin L, Moliterno D, Armstrong P, White H, Held C, Aylward P, Werf FVd, Harrington R, Mahaffey K, Tricoci P. Tradeoff Between Myocardial Infarction Versus Bleeding Types On Mortality After Acute Coronary Syndrome: Lessons From The Thrombin Receptor Antagonist For Clinical Event Reduction In Acute Coronary Syndrome (Tracer) Randomized Trial Journal of the American College of Cardiology. 67: 456-456. DOI: 10.1016/S0735-1097(16)30457-0 |
0.384 |
|
| 2016 |
Mehta RH, Sun J, Lokhnygina Y, Watkins K, Roe M, Corbalán R, Blazing M. The Association Of High-Density Lipoprotein Cholesterol With Long-Term Adverse Events Among Patients With Established Coronary Artery Disease: Insights From The Improve-It Trial Journal of the American College of Cardiology. 67: 447. DOI: 10.1016/S0735-1097(16)30448-X |
0.343 |
|
| 2015 |
Halim SA, Clare RM, Newby LK, Lokhnygina Y, Schweiger MJ, Hof AW, Hochman JS, James SK, White HD, Widimsky P, Betriu A, Bode C, Giugliano RP, Harrington RA, Zeymer U. Frequency, clinical and angiographic characteristics, and outcomes of high-risk non-ST-segment elevation acute coronary syndromes patients with left circumflex culprit lesions. International Journal of Cardiology. 203: 708-713. PMID 26587725 DOI: 10.1016/J.Ijcard.2015.11.036 |
0.354 |
|
| 2015 |
Nicolau JC, Bhatt DL, Roe MT, Lokhnygina Y, Neely B, Corbalán R, Leiva-Pons JL, Martinez F, Goodman SG, Winters KJ, Verheugt FW, Armstrong PW, White HD, Fox KA, Prabhakaran D, et al. Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial. American Heart Journal. 170: 683-694.e3. PMID 26386792 DOI: 10.1016/J.Ahj.2015.05.017 |
0.424 |
|
| 2015 |
Bansilal S, Bloomgarden Z, Halperin JL, Hellkamp AS, Lokhnygina Y, Patel MR, Becker RC, Breithardt G, Hacke W, Hankey GJ, Nessel CC, Singer DE, Berkowitz SD, Piccini JP, Mahaffey KW, et al. Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: The Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial). American Heart Journal. 170: 675-682.e8. PMID 26386791 DOI: 10.1016/J.Ahj.2015.07.006 |
0.369 |
|
| 2015 |
Wieslander B, Nijveldt R, Klem I, Lokhnygina Y, Pura J, Wagner GS, Ugander M, Atwater BD. Evaluation of Selvester QRS score for use in presence of conduction abnormalities in a broad population. American Heart Journal. 170: 346-52. PMID 26299233 DOI: 10.1016/J.Ahj.2015.05.005 |
0.327 |
|
| 2015 |
Daneshmand MA, Krishnamoorthy A, Samsky MD, Felker GM, Pura JA, Lokhnygina Y, Hernandez AF, Rosenberg PB, Blue LJ, Schroder JN, Rogers JG, Milano CA, Patel CB. Comparison of 2-Year Outcomes of Extended Criteria Cardiac Transplantation Versus Destination Left Ventricular Assist Device Therapy Using Continuous Flow. The American Journal of Cardiology. PMID 26092273 DOI: 10.1016/J.Amjcard.2015.05.016 |
0.338 |
|
| 2015 |
Bagai A, Huang Z, Lokhnygina Y, Harrington RA, Armstrong PW, Strony J, White HD, Leonardi S, Held C, Van de Werf F, Wallentin L, Tricoci P, Mahaffey KW. Magnitude of troponin elevation and long-term clinical outcomes in acute coronary syndrome patients treated with and without revascularization. Circulation. Cardiovascular Interventions. 8: e002314. PMID 26025218 DOI: 10.1161/Circinterventions.115.002314 |
0.402 |
|
| 2015 |
Cornel JH, Tricoci P, Lokhnygina Y, Moliterno DJ, Wallentin L, Armstrong PW, Aylward PE, Clare RM, Chen E, Leonardi S, Van de Werf F, White HD, Held C, Strony J, Mahaffey KW, et al. Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial). The American Journal of Cardiology. 115: 1325-32. PMID 25776457 DOI: 10.1016/J.Amjcard.2015.02.043 |
0.378 |
|
| 2015 |
Washam JB, Stevens SR, Lokhnygina Y, Halperin JL, Breithardt G, Singer DE, Mahaffey KW, Hankey GJ, Berkowitz SD, Nessel CC, Fox KA, Califf RM, Piccini JP, Patel MR. Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Lancet (London, England). 385: 2363-70. PMID 25749644 DOI: 10.1016/S0140-6736(14)61836-5 |
0.375 |
|
| 2015 |
Singer DE, Hellkamp AS, Yuan Z, Lokhnygina Y, Patel MR, Piccini JP, Hankey GJ, Breithardt G, Halperin JL, Becker RC, Hacke W, Nessel CC, Mahaffey KW, Fox KA, Califf RM, et al. Alternative calculations of individual patient time in therapeutic range while taking warfarin: results from the ROCKET AF trial. Journal of the American Heart Association. 4: e001349. PMID 25736441 DOI: 10.1161/Jaha.114.001349 |
0.326 |
|
| 2015 |
Steinberg BA, Hellkamp AS, Lokhnygina Y, Patel MR, Breithardt G, Hankey GJ, Becker RC, Singer DE, Halperin JL, Hacke W, Nessel CC, Berkowitz SD, Mahaffey KW, Fox KA, Califf RM, et al. Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial. European Heart Journal. 36: 288-96. PMID 25209598 DOI: 10.1093/Eurheartj/Ehu359 |
0.374 |
|
| 2015 |
Bakal JA, Roe MT, Ohman EM, Goodman SG, Fox KA, Zheng Y, Westerhout CM, Hochman JS, Lokhnygina Y, Brown EB, Armstrong PW. Applying novel methods to assess clinical outcomes: insights from the TRILOGY ACS trial. European Heart Journal. 36: 385-92a. PMID 25012156 DOI: 10.1093/Eurheartj/Ehu262 |
0.317 |
|
| 2015 |
Huang KT, Martin J, Marky A, Chagoya G, Hatef J, Hazzard MA, Thomas SM, Lokhnygina Y, Lad SP. A national survey of spinal cord stimulation trial-to-permanent conversion rates. Neuromodulation : Journal of the International Neuromodulation Society. 18: 133-9; discussion 13. PMID 24930992 DOI: 10.1111/Ner.12199 |
0.348 |
|
| 2014 |
LaPointe NM, Lokhnygina Y, Rimmler J, Sanders GD, Peterson ED, Al-Khatib SM. Use Of Rate And Rhythm Control Drugs In Patients Younger Than 65 Years With Atrial Fibrillation. Journal of Atrial Fibrillation. 7: 1062. PMID 27957082 DOI: 10.4022/Jafib.1062 |
0.343 |
|
| 2014 |
Tricoci P, Lokhnygina Y, Huang Z, Van de Werf F, Cornel JH, Chen E, Wallentin L, Held C, Aylward PE, Moliterno DJ, Jennings LK, White HD, Armstrong PW, Harrington RA, Strony J, et al. Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial. American Heart Journal. 168: 869-77.e1. PMID 25458650 DOI: 10.1016/J.Ahj.2014.09.002 |
0.382 |
|
| 2014 |
Breithardt G, Baumgartner H, Berkowitz SD, Hellkamp AS, Piccini JP, Stevens SR, Lokhnygina Y, Patel MR, Halperin JL, Singer DE, Hankey GJ, Hacke W, Becker RC, Nessel CC, Mahaffey KW, et al. Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. European Heart Journal. 35: 3377-85. PMID 25148838 DOI: 10.1093/Eurheartj/Ehu305 |
0.375 |
|
| 2014 |
Piccini JP, Al-Khatib SM, Wojdyla DM, Shaw LK, Horton JR, Lokhnygina Y, Anstrom KJ, DeWald T, Allen-LaPointe N, Steinberg BA, Thomas K, Daubert JP, Peterson ED. Comparison of safety of sotalol versus amiodarone in patients with atrial fibrillation and coronary artery disease. The American Journal of Cardiology. 114: 716-22. PMID 25129065 DOI: 10.1016/J.Amjcard.2014.06.004 |
0.568 |
|
| 2014 |
Valgimigli M, Tricoci P, Huang Z, Aylward PE, Armstrong PW, Van de Werf F, Leonardi S, White HD, Widimsky P, Harrington RA, Cequier A, Chen E, Lokhnygina Y, Wallentin L, Strony J, et al. Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER Trial). The American Journal of Cardiology. 114: 665-73. PMID 25129064 DOI: 10.1016/J.Amjcard.2014.05.054 |
0.431 |
|
| 2014 |
White HD, Huang Z, Tricoci P, Van de Werf F, Wallentin L, Lokhnygina Y, Moliterno DJ, Aylward PE, Mahaffey KW, Armstrong PW. Reduction in overall occurrences of ischemic events with vorapaxar: results from TRACER. Journal of the American Heart Association. 3. PMID 25012288 DOI: 10.1161/Jaha.114.001032 |
0.362 |
|
| 2014 |
Halperin JL, Hankey GJ, Wojdyla DM, Piccini JP, Lokhnygina Y, Patel MR, Breithardt G, Singer DE, Becker RC, Hacke W, Paolini JF, Nessel CC, Mahaffey KW, Califf RM, Fox KA, et al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Circulation. 130: 138-46. PMID 24895454 DOI: 10.1161/Circulationaha.113.005008 |
0.36 |
|
| 2014 |
Ilowite NT, Prather K, Lokhnygina Y, Schanberg LE, Elder M, Milojevic D, Verbsky JW, Spalding SJ, Kimura Y, Imundo LF, Punaro MG, Sherry DD, Tarvin SE, Zemel LS, Birmingham JD, et al. Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis. Arthritis & Rheumatology (Hoboken, N.J.). 66: 2570-9. PMID 24839206 DOI: 10.1002/Art.38699 |
0.303 |
|
| 2014 |
Steinberg BA, Hellkamp AS, Lokhnygina Y, Halperin JL, Breithardt G, Passman R, Hankey GJ, Patel MR, Becker RC, Singer DE, Hacke W, Berkowitz SD, Nessel CC, Mahaffey KW, Fox KA, et al. Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: results from the ROCKET AF trial. Heart Rhythm : the Official Journal of the Heart Rhythm Society. 11: 925-32. PMID 24833235 DOI: 10.1016/J.Hrthm.2014.03.006 |
0.353 |
|
| 2014 |
Piccini JP, Hellkamp AS, Lokhnygina Y, Patel MR, Harrell FE, Singer DE, Becker RC, Breithardt G, Halperin JL, Hankey GJ, Berkowitz SD, Nessel CC, Mahaffey KW, Fox KA, Califf RM, et al. Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial. Journal of the American Heart Association. 3: e000521. PMID 24755148 DOI: 10.1161/Jaha.113.000521 |
0.333 |
|
| 2014 |
Hankey GJ, Stevens SR, Piccini JP, Lokhnygina Y, Mahaffey KW, Halperin JL, Patel MR, Breithardt G, Singer DE, Becker RC, Berkowitz SD, Paolini JF, Nessel CC, Hacke W, Fox KA, et al. Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation. Stroke; a Journal of Cerebral Circulation. 45: 1304-12. PMID 24743444 DOI: 10.1161/Strokeaha.113.004506 |
0.331 |
|
| 2014 |
Piccini JP, Garg J, Patel MR, Lokhnygina Y, Goodman SG, Becker RC, Berkowitz SD, Breithardt G, Hacke W, Halperin JL, Hankey GJ, Nessel CC, Mahaffey KW, Singer DE, Califf RM, et al. Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. European Heart Journal. 35: 1873-80. PMID 24658769 DOI: 10.1093/Eurheartj/Ehu083 |
0.358 |
|
| 2014 |
Sherwood MW, Douketis JD, Patel MR, Piccini JP, Hellkamp AS, Lokhnygina Y, Spyropoulos AC, Hankey GJ, Singer DE, Nessel CC, Mahaffey KW, Fox KA, Califf RM, Becker RC. Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). Circulation. 129: 1850-9. PMID 24552831 DOI: 10.1161/Circulationaha.113.005754 |
0.373 |
|
| 2013 |
Allen LaPointe NM, Lokhnygina Y, Sanders GD, Peterson ED, Al-Khatib SM. Adherence to guideline recommendations for antiarrhythmic drugs in atrial fibrillation. American Heart Journal. 166: 871-8. PMID 24176443 DOI: 10.1016/J.Ahj.2013.08.010 |
0.308 |
|
| 2013 |
Piccini JP, Stevens SR, Chang Y, Singer DE, Lokhnygina Y, Go AS, Patel MR, Mahaffey KW, Halperin JL, Breithardt G, Hankey GJ, Hacke W, Becker RC, Nessel CC, Fox KA, et al. Response to letter regarding article, "renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study cohorts". Circulation. 128: e172-3. PMID 24019452 DOI: 10.1161/Circulationaha.113.004013 |
0.331 |
|
| 2013 |
Bagai A, White JA, Lokhnygina Y, Giugliano RP, Van de Werf F, Montalescot G, Armstrong PW, Tricoci P, Gibson CM, Califf RM, Harrington RA, Newby LK. Routine early eptifibatide versus delayed provisional use at percutaneous coronary intervention in high-risk non-ST-segment elevation acute coronary syndromes patients: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome trial. American Heart Journal. 166: 466-73. PMID 24016495 DOI: 10.1016/J.Ahj.2013.05.019 |
0.387 |
|
| 2013 |
Wiviott SD, White HD, Ohman EM, Fox KA, Armstrong PW, Prabhakaran D, Hafley G, Lokhnygina Y, Boden WE, Hamm C, Clemmensen P, Nicolau JC, Menozzi A, Ruzyllo W, Widimsky P, et al. Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial. Lancet (London, England). 382: 605-13. PMID 23953385 DOI: 10.1016/S0140-6736(13)61451-8 |
0.419 |
|
| 2013 |
Piccini JP, White JA, Mehta RH, Lokhnygina Y, Al-Khatib SM, Tricoci P, Califf RM, Harrington RA, Newby LK, Pollack CV, Montalescot G, Van de Werf F, Gibson CM, Giugliano RP. Response to letter regarding article, “sustained ventricular tachycardia and ventricular fibrillation complicating non–ST-segment elevation acute coronary syndromes”. Circulation. 127: e634. PMID 23833786 DOI: 10.1161/Circulationaha.112.147546 |
0.377 |
|
| 2013 |
Lopes RD, Lokhnygina Y, Hasselblad V, Newby KL, Yow E, Granger CB, Armstrong PW, Hochman JS, Mills JS, Ruzyllo W, Mahaffey KW. Methods of creatine kinase-MB analysis to predict mortality in patients with myocardial infarction treated with reperfusion therapy. Trials. 14: 123. PMID 23782531 DOI: 10.1186/1745-6215-14-123 |
0.32 |
|
| 2013 |
Singer DE, Hellkamp AS, Piccini JP, Mahaffey KW, Lokhnygina Y, Pan G, Halperin JL, Becker RC, Breithardt G, Hankey GJ, Hacke W, Nessel CC, Patel MR, Califf RM, Fox KA, et al. Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial. Journal of the American Heart Association. 2: e000067. PMID 23525418 DOI: 10.1161/Jaha.112.000067 |
0.355 |
|
| 2013 |
Piccini JP, Stevens SR, Lokhnygina Y, Patel MR, Halperin JL, Singer DE, Hankey GJ, Hacke W, Becker RC, Nessel CC, Mahaffey KW, Fox KA, Califf RM, Breithardt G. Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. Journal of the American College of Cardiology. 61: 1998-2006. PMID 23500298 DOI: 10.1016/J.Jacc.2013.02.025 |
0.356 |
|
| 2013 |
Leonardi S, Stebbins A, Lopes RD, Lokhnygina Y, Todd M, Bhatt DL, Stone GW, Lincoff AM, Dauerman HL, Gibson CM, White HD, Parikh KH, Gruberg L, Herrmann HC, McLaurin BT, et al. Quantification of the effect of clopidogrel on enzymatic infarct size related to a percutaneous coronary intervention in patients with acute coronary syndromes: insights from the CHAMPION percutaneous coronary intervention trial. Coronary Artery Disease. 24: 321-7. PMID 23442944 DOI: 10.1097/Mca.0B013E32835F2Fbd |
0.347 |
|
| 2013 |
Patel MR, Hellkamp AS, Lokhnygina Y, Piccini JP, Zhang Z, Mohanty S, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Becker RC, Nessel CC, Berkowitz SD, Califf RM, et al. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). Journal of the American College of Cardiology. 61: 651-8. PMID 23391196 DOI: 10.1016/J.Jacc.2012.09.057 |
0.377 |
|
| 2013 |
Piccini JP, Stevens SR, Chang Y, Singer DE, Lokhnygina Y, Go AS, Patel MR, Mahaffey KW, Halperin JL, Breithardt G, Hankey GJ, Hacke W, Becker RC, Nessel CC, Fox KA, et al. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. Circulation. 127: 224-32. PMID 23212720 DOI: 10.1161/Circulationaha.112.107128 |
0.333 |
|
| 2013 |
Chan MY, Sun JL, Newby LK, Lokhnygina Y, White HD, Moliterno DJ, Théroux P, Ohman EM, Simoons ML, Mahaffey KW, Pieper KS, Giugliano RP, Armstrong PW, Califf RM, Van de Werf F, et al. Trends in clinical trials of non-ST-segment elevation acute coronary syndromes over 15 years. International Journal of Cardiology. 167: 548-54. PMID 22341697 DOI: 10.1016/J.Ijcard.2012.01.065 |
0.424 |
|
| 2013 |
White HD, Huang Z, Tricoci P, Werf FVD, Wallentin L, Lokhnygina Y, Moliterno D, Aylward PE, Mahaffey K, Armstrong PW. Reduction in recurrent ischemic events with vorapaxar: results from TRACER European Heart Journal. 34: 880-880. DOI: 10.1093/Eurheartj/Eht310.P4842 |
0.358 |
|
| 2013 |
Breithardt G, Berkowitz S, Baumgartner H, Hellkamp A, Piccini J, Stevens S, Lokhnygina Y, Patel M, Halperin J, Singer D, Hankey G, Hacke W, Becker R, Nessel C, Mahaffey K, et al. OUTCOMES OF PATIENTS WITH ATRIAL FIBRILLATION AND SIGNIFICANT VALVULAR LESIONS: COMPARISON OF THE EFFECTS OF RIVAROXABAN AND WARFARIN IN THE ROCKET AF TRIAL Journal of the American College of Cardiology. 61: E339. DOI: 10.1016/S0735-1097(13)60339-3 |
0.352 |
|
| 2013 |
Sherwood MW, Hellkamp A, Patel M, Piccini J, Lokhnygina Y, Douketis J, Becker R, Mahaffey K, Fox K, Califf R. Outcomes Of Temporary Interruptions Of Rivaroxaban Or Warfarin In Patients With Atrial Fibrillation In The Rocket Af Trial Journal of the American College of Cardiology. 61. DOI: 10.1016/S0735-1097(13)60316-2 |
0.38 |
|
| 2013 |
Breithardt G, Baumgartner H, Berkowitz S, Hellkamp A, Piccini J, Stevens S, Lokhnygina Y, Patel M, Halperin J, Singer D, Hankey G, Hacke W, Becker R, Nessel C, Mahaffey K, et al. CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH ATRIAL FIBRILLATION AND SIGNIFICANT VALVULAR LESIONS: EXPERIENCE FROM THE ROCKET AF TRIAL Journal of the American College of Cardiology. 61: E282. DOI: 10.1016/S0735-1097(13)60282-X |
0.341 |
|
| 2013 |
Hess PL, Tricoci P, Horton J, Lokhnygina Y, Al-Khatib SM, Piccini J, Harrington R, Armstrong P, Aylward P, Moliterno D, Werf FVd, Wallentin L, White H, Held C, Mahaffey K. Incidence And Predictors Of Sudden Cardiac Death After Hospitalization For Non-St-Segment Elevation Myocardial Infarction: An Analysis From The Tracer Trial Journal of the American College of Cardiology. 61. DOI: 10.1016/S0735-1097(13)60110-2 |
0.338 |
|
| 2013 |
Cornel JH, Tricoci P, Horton j, Moliterno D, Wallentin L, Armstrong P, Aylward P, Huang Z, Lokhnygina Y, Chen E, Leonardi S, Werf FVd, White H, Held C, Strony J, et al. Effects Of Glycoprotein Iib/Iiia Inhibitors In Combination With Vorapaxar, A Platelet Thrombin-Receptor Antagonist, Among Patients With Non-St-Segment Elevation Acute Coronary Syndromes: Insights From The Tracer Trial Journal of the American College of Cardiology. 61. DOI: 10.1016/S0735-1097(13)60103-5 |
0.371 |
|
| 2012 |
Roe MT, Armstrong PW, Fox KA, White HD, Prabhakaran D, Goodman SG, Cornel JH, Bhatt DL, Clemmensen P, Martinez F, Ardissino D, Nicolau JC, Boden WE, Gurbel PA, Ruzyllo W, ... ... Lokhnygina Y, et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. The New England Journal of Medicine. 367: 1297-309. PMID 22920930 DOI: 10.1056/Nejmoa1205512 |
0.361 |
|
| 2012 |
Piccini JP, White JA, Mehta RH, Lokhnygina Y, Al-Khatib SM, Tricoci P, Pollack CV, Montalescot G, Van de Werf F, Gibson CM, Giugliano RP, Califf RM, Harrington RA, Newby LK. Sustained ventricular tachycardia and ventricular fibrillation complicating non-ST-segment-elevation acute coronary syndromes. Circulation. 126: 41-9. PMID 22645292 DOI: 10.1161/Circulationaha.111.071860 |
0.355 |
|
| 2012 |
Roe MT, White JA, Kaul P, Tricoci P, Lokhnygina Y, Miller CD, van't Hof AW, Montalescot G, James SK, Saucedo J, Ohman EM, Pollack CV, Hochman JS, Armstrong PW, Giugliano RP, et al. Regional patterns of use of a medical management strategy for patients with non-ST-segment elevation acute coronary syndromes: insights from the EARLY ACS Trial. Circulation. Cardiovascular Quality and Outcomes. 5: 205-13. PMID 22373905 DOI: 10.1161/Circoutcomes.111.962332 |
0.359 |
|
| 2012 |
Mills JS, Mahaffey KW, Lokhnygina Y, Nicolau JC, Ruzyllo W, Adams PX, Todaro TG, Armstrong PW, Granger CB. Prediction of enzymatic infarct size in ST-segment elevation myocardial infarction. Coronary Artery Disease. 23: 118-25. PMID 22217457 DOI: 10.1097/Mca.0B013E32834E4F8F |
0.345 |
|
| 2012 |
Jolicœur EM, Sketch MJ, Wojdyla DM, Javaheri SP, Nosib S, Lokhnygina Y, Patel MR, Shaw LK, Tcheng JE. Percutaneous coronary interventions and cardiovascular outcomes for patients with chronic total occlusions. Catheterization and Cardiovascular Interventions : Official Journal of the Society For Cardiac Angiography & Interventions. 79: 603-12. PMID 21805595 DOI: 10.1002/Ccd.23269 |
0.346 |
|
| 2012 |
Goodman SG, Roe MT, Armstrong PW, White HD, Fox KA, Prabhakaran D, Brown E, Lokhnygina Y, Ohman E. 903 The Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) Trial Canadian Journal of Cardiology. 28. DOI: 10.1016/J.Cjca.2012.07.743 |
0.418 |
|
| 2011 |
Mahaffey KW, Pieper KS, Lokhnygina Y, Califf RM, Antman EM, Kleiman NS, Goodman SG, White HD, Rao SV, Hochman JS, Cohen M, Col JJ, Roe MT, Ferguson JJ. The impact of postrandomization crossover of therapy in acute coronary syndromes care. Circulation. Cardiovascular Quality and Outcomes. 4: 211-9. PMID 21304094 DOI: 10.1161/Circoutcomes.109.853598 |
0.395 |
|
| 2010 |
Chin CT, Roe MT, Fox KA, Prabhakaran D, Marshall DA, Petitjean H, Lokhnygina Y, Brown E, Armstrong PW, White HD, Ohman EM. Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial. American Heart Journal. 160: 16-22.e1. PMID 20598967 DOI: 10.1016/J.Ahj.2010.04.022 |
0.424 |
|
| 2010 |
Califf RM, Lokhnygina Y, Cannon CP, Stepanavage ME, McCabe CH, Musliner TA, Pasternak RC, Blazing MA, Giugliano RP, Harrington RA, Braunwald E. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design. American Heart Journal. 159: 705-9. PMID 20435175 DOI: 10.1016/J.Ahj.2010.03.004 |
0.301 |
|
| 2009 |
Califf RM, Lokhnygina Y, Velazquez EJ, McMurray JJ, Leimberger JD, Lewis EF, Diaz R, Murin J, Pfeffer MA. Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial). The American Journal of Cardiology. 104: 151-7. PMID 19576338 DOI: 10.1016/J.Amjcard.2009.03.020 |
0.342 |
|
| 2009 |
Kandzari DE, Rao SV, Moses JW, Dzavik V, Strauss BH, Kutryk MJ, Simonton CA, Garg J, Lokhnygina Y, Mancini GB, Yeoh E, Buller CE. Clinical and angiographic outcomes with sirolimus-eluting stents in total coronary occlusions: the ACROSS/TOSCA-4 (Approaches to Chronic Occlusions With Sirolimus-Eluting Stents/Total Occlusion Study of Coronary Arteries-4) trial. Jacc. Cardiovascular Interventions. 2: 97-106. PMID 19463409 DOI: 10.1016/J.Jcin.2008.10.013 |
0.327 |
|
| 2008 |
Thomas KL, Al-Khatib SM, Lokhnygina Y, Solomon SD, Kober L, McMurray JJ, Califf RM, Velazquez EJ. Amiodarone use after acute myocardial infarction complicated by heart failure and/or left ventricular dysfunction may be associated with excess mortality. American Heart Journal. 155: 87-93. PMID 18082495 DOI: 10.1016/J.Ahj.2007.09.010 |
0.349 |
|
| 2007 |
Tricoci P, Lokhnygina Y, Berdan LG, Steinhubl SR, Gulba DC, White HD, Kleiman NS, Aylward PE, Langer A, Califf RM, Ferguson JJ, Antman EM, Newby LK, Harrington RA, Goodman SG, et al. Time to coronary angiography and outcomes among patients with high-risk non ST-segment elevation acute coronary syndromes: results from the SYNERGY trial. Circulation. 116: 2669-77. PMID 18025532 DOI: 10.1161/Circulationaha.107.690081 |
0.386 |
|
| 2007 |
Mehta RH, Greenbaum AB, Lokhnygina Y, Newby LK, Van De Werf F, Armstrong PW, Pieper KS, Califf RM, Granger CB, Harrington RA. Timing of death and myocardial infarction in patients with non-ST elevation acute coronary syndromes: insights from randomized clinical trials. Journal of Interventional Cardiology. 20: 299-306. PMID 17880325 DOI: 10.1111/J.1540-8183.2007.00277.X |
0.389 |
|
| 2007 |
Sampson UK, Pfeffer MA, McMurray JJ, Lokhnygina Y, White HD, Solomon SD. Predictors of stroke in high-risk patients after acute myocardial infarction: insights from the VALIANT Trial. European Heart Journal. 28: 685-91. PMID 16984929 DOI: 10.1093/Eurheartj/Ehl197 |
0.368 |
|
| 2006 |
White HD, Kleiman NS, Mahaffey KW, Lokhnygina Y, Pieper KS, Chiswell K, Cohen M, Harrington RA, Chew DP, Petersen JL, Berdan LG, Aylward PE, Nessel CC, Ferguson JJ, Califf RM. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial. American Heart Journal. 152: 1042-50. PMID 17161049 DOI: 10.1016/J.Ahj.2006.08.002 |
0.424 |
|
| Show low-probability matches. |